JOHNSON & JOHNSON

Overview

Johnson & Johnson is a global healthcare company that researches, develops, manufactures and sells a broad range of products related to human health and well-being, and it conducts business in virtually all countries of the world.[1] The company is organized into two core segments: Innovative Medicine, which focuses on prescription therapies in areas such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular/metabolism, and MedTech, which includes products used in orthopaedics, surgery, cardiovascular care, and vision.[2] Guided by its Credo, Johnson & Johnson states that “health is everything” and frames its mission around preventing, treating and curing complex diseases while advancing smarter, less invasive and more personalized healthcare solutions.[3]

Johnson & Johnson is one of the largest healthcare companies globally: in 2024 it generated $88.8 billion in worldwide sales and had approximately 138,100 employees worldwide.[4][1] Its geographic footprint is broad, with the United States as its largest market at $50.3 billion of 2024 sales and international operations contributing $38.5 billion, including significant business in Europe, the Western Hemisphere outside the U.S., and Asia-Pacific/Africa.[5][6] [1]+5

Products & services

Johnson & Johnson’s products are concentrated in prescription medicines and medical technology. In Innovative Medicine, named products include SIMPONI, a subcutaneous treatment for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis; SIMPONI ARIA, an intravenous version for related inflammatory conditions; STELARA for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis; and TREMFYA for plaque psoriasis, psoriatic arthritis and ulcerative colitis. The neuroscience portfolio includes SPRAVATO, a nasal spray used with an oral antidepressant for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with suicidal thoughts or actions. Oncology products include CARVYKTI, a CAR-T-cell therapy for relapsed/refractory multiple myeloma; DARZALEX and DARZALEX FASPRO for multiple myeloma, with FASPRO also indicated for light-chain amyloidosis; TECVAYLI, a ready-to-use bispecific antibody for relapsed or refractory multiple myeloma after at least four prior lines of therapy; ERLEADA for prostate cancer; and IMBRUVICA for certain B-cell malignancies and chronic graft-versus-host disease. Other major medicines include XARELTO, an oral anticoagulant used across DVT/PE prevention and treatment, atrial fibrillation, CAD/PAD and certain pediatric thromboembolism settings, plus OPSUMIT and UPTRAVI for pulmonary arterial hypertension.[7][8]

In 2024, Innovative Medicine generated $56.964 billion of sales and MedTech generated $31.857 billion, implying roughly 64% of company sales came from medicines and 36% from MedTech. Product concentration was meaningful: DARZALEX generated $11.670 billion of sales, or about 13% of total company sales, and STELARA generated $10.361 billion, or about 12%; other sizable products included TREMFYA at $3.670 billion, IMBRUVICA at $3.038 billion, ERLEADA at $2.999 billion, XARELTO at $2.373 billion, OPSUMIT at $2.184 billion, UPTRAVI at $1.817 billion, SPRAVATO at $1.077 billion and CARVYKTI at $963 million.[9][10]

The MedTech portfolio covers cardiovascular, orthopaedics, surgery and vision products. Cardiovascular includes electrophysiology products for heart-rhythm disorders, Abiomed heart-recovery technologies for severe coronary artery disease requiring high-risk PCI or for AMI cardiogenic shock, Shockwave circulatory-restoration products for calcified coronary and peripheral artery disease, and neurovascular products used in hemorrhagic and ischemic stroke care. Orthopaedics includes products and enabling technologies for hips, knees, trauma, spine and sports medicine, and the franchise specifically cites pull-through from the VELYS robotic-assisted solution; Surgery includes advanced and general surgery technologies as well as Mentor breast aesthetics and reconstruction solutions, with growth linked in part to a differentiated wound-closure portfolio; Vision includes ACUVUE contact lenses and TECNIS intraocular lenses for cataract surgery. In 2024, Surgery generated $9.8 billion of sales, Orthopaedics $9.2 billion, Cardiovascular $7.7 billion and Vision $5.1 billion.[11]+4 [7]+8

Geographic presence

Johnson & Johnson conducts business in virtually all countries of the world, and its principal executive offices are at One Johnson & Johnson Plaza in New Brunswick, New Jersey. Its international operations sell products developed both in the United States and by subsidiaries abroad, with markets, products, and distribution methods varying by country and culture.[16][17]

In 2024, worldwide sales were $88.8 billion, of which $50.3 billion, or 56.6%, came from the United States; $20.2 billion, or 22.8%, from Europe; $13.6 billion, or 15.3%, from Asia-Pacific and Africa; and $4.7 billion, or 5.3%, from the Western Hemisphere excluding the United States. This implies that 43.4% of sales were generated outside the U.S.[6]

Its manufacturing footprint includes 64 facilities totaling about 9.6 million square feet, distributed across the United States (23 facilities), Europe (21), the Western Hemisphere excluding the U.S. (7), and Africa, Asia and the Pacific (13). Beyond manufacturing, the company also maintains numerous office and warehouse facilities throughout the world, and it had approximately 139,800 employees globally as of December 29, 2024.[18]+5 [16]+8

Business segments

Johnson & Johnson currently reports two official business segments: Innovative Medicine and MedTech. Innovative Medicine is organized around the therapeutic areas of Immunology, Infectious Diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolism, while MedTech covers Orthopaedics, Surgery, Cardiovascular, and Vision; the company notes that the Cardiovascular field was previously referred to as Interventional Solutions [2]+2.

Based on full-year 2024 sales, Innovative Medicine contributed about 64.1% of company sales ($56.964 billion) and MedTech about 35.9% ($31.857 billion) [24]. Within MedTech, Johnson & Johnson further describes four major franchises: Surgery, which includes advanced and general surgery technologies plus breast aesthetics and reconstruction; Orthopaedics, which includes hips, knees, trauma, spine, sports, and related technologies; Cardiovascular, which includes electrophysiology, heart recovery, circulatory restoration, and neurovascular care; and Vision, which includes ACUVUE contact lenses and TECNIS intraocular lenses [11]. In 2024, those MedTech franchises generated about $9.8 billion in Surgery, $9.2 billion in Orthopaedics, $7.7 billion in Cardiovascular, and $5.1 billion in Vision sales, illustrating that the segment is relatively diversified across its four main categories [13]+3. [2]+7

Company history

Johnson & Johnson was founded in 1886 by brothers Robert Wood Johnson, James Wood Johnson and Edward Mead Johnson, and it was incorporated in New Jersey in 1887.[25][1] An early milestone came in 1920 with the introduction of BAND-AID brand adhesive bandages, one of the company’s best-known consumer products.[26]

In the postwar period, the company expanded through acquisitions that helped shape its consumer and pharmaceutical operations. Johnson & Johnson acquired McNeil Laboratories in 1959; McNeil had introduced TYLENOL in 1955.[27][28] It acquired Janssen Pharmaceutica in 1961, broadening its presence in prescription medicines, and later added biotechnology capabilities through the acquisition of Centocor in 1999.[29][30]

Johnson & Johnson also built its medical technology business through acquisitions, including DePuy in 1998 and Synthes in 2012, which together became the basis of DePuy Synthes in orthopaedics.[31][32] More recently, the company separated most of its consumer health business through Kenvue’s 2023 IPO and subsequent exchange offer; by 2024, Johnson & Johnson no longer held Kenvue shares.[33]+2 [1]+11

Sources

• JOHNSON & JOHNSON — Full financial report (2024 Y)
  25 citations

  [1][2][3][4][5][6][7][8][10][11][12][13][14][15][16][17][18][19][20][21][22][23][33][34][35]
• JOHNSON & JOHNSON — Additional data (2024 Y)[9]
• JOHNSON & JOHNSON — Press release (2024 Y)[24]
• ourstory.jnj.com[25]
• ourstory.jnj.com[26]
• ourstory.jnj.com[27]
• ourstory.jnj.com[28]
• ourstory.jnj.com[29]
• ourstory.jnj.com[30]
• ourstory.jnj.com[31]
• ourstory.jnj.com[32]